Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study - Top-Institutions - MDSpire

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study

  • By

  • Kazuyuki Mizuno

  • Basile Chretien

  • Kazuki Nishida

  • Takanori Ito

  • Hiroki Kawashima

  • Yuichi Ando

  • June 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Gastroenterology
    • Hepatology

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Gastroenterology

  • #3

    University of Miami Sylvester Comprehensive Cancer Center
    University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

    Key Differentiators

    • Gastroenterology
    • Oncology

  • #4

    The Royal Marsden Hospital
    The Royal Marsden Hospital

    London, England

    Key Differentiators

    • Oncology
    • Gastroenterology

  • #5

    Kobe University
    Kobe University

    Kobe, Japan

    Key Differentiators

    • Gastroenterology

Original Source(s)

Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study

  • by Kazuyuki Mizuno, Basile Chretien, Kazuki Nishida, Takanori Ito, Hiroki Kawashima, Yuichi Ando

  • June 26, 2026

Related Content

Photographic assessment of urostomy characteristics after ileal conduit diversion: a feasibility study

Joseph Fraumeni Jr., pioneering cancer genetics researcher, devoted his life to families like mine

Clinical and prognostic implications of pituitary tumor-transforming gene 1 in solid tumors